DI Markus Roucka

Head Business Development
Tentamus Pharma DACH, Austria
Markus initiated his career in the biotechnical laboratories of Biomin GmbH, Austria as Lab technician in the R&D department. He was responsible for manufacturing and QC processes of the products. After almost 5 years he decided to attend University of Applied Science to study “Medical and Pharmaceutical Biotechnology” at the IMC Krems, Austria. For his Master thesis Markus went to The Netherlands and studied the effect of the TRIAL-ligand in combination with Bortezomib on NSCLC. After that he changed from green to the red biotechnology and started his career at VelaLabs in 2008 as Senior technician in the QC department, responsible for qualification and validation of assays for large molecules. Afterwards he was 8 years Head of Laboratory installing Projects and QC processes and afterwards two years Chief Operating Officer (COO). After the foundation of a Business Development Group within VelaLabs and increased further business, he became Managing Director of VelaLabs in Vienna between 2019-2023 thereby managing up to 95 employees. His current position now in the Tentamus Group as Head Business Development responsible for further strategic decisions within the Tentamus Pharma Group.

Events/Masterclasses DI Markus Roucka is currently speaking at

Pharma

CMC Analytical Comparability: Methods & Strategies for Biologics
23 - 24 January 2024
Vienna, Austria | Online Live Stream | 9:00 CET – 17:30 CET
Join our CMC Analytical Comparability training led by experts to understand principles of protein structure and comparative analytics.

Are you interested in a custom-made event with this trainer?

Contact us to Request more information about your custom-made Corporate Learning program.

REQUEST MORE INFORMATION

DI Markus Roucka
Head Business Development
Tentamus Pharma DACH, Austria
Markus initiated his career in the biotechnical laboratories of Biomin GmbH, Austria as Lab technician in the R&D department. He was responsible for manufacturing and QC processes of the products. After almost 5 years he decided to attend University of Applied Science to study “Medical and Pharmaceutical Biotechnology” at the IMC Krems, Austria. For his Master thesis Markus went to The Netherlands and studied the effect of the TRIAL-ligand in combination with Bortezomib on NSCLC. After that he changed from green to the red biotechnology and started his career at VelaLabs in 2008 as Senior technician in the QC department, responsible for qualification and validation of assays for large molecules. Afterwards he was 8 years Head of Laboratory installing Projects and QC processes and afterwards two years Chief Operating Officer (COO). After the foundation of a Business Development Group within VelaLabs and increased further business, he became Managing Director of VelaLabs in Vienna between 2019-2023 thereby managing up to 95 employees. His current position now in the Tentamus Group as Head Business Development responsible for further strategic decisions within the Tentamus Pharma Group.
DI Markus Roucka
Description